Aim To investigate the association between type 2 diabetes mellitus (T2DM) and pulmonary embolism, as well as to determine the prognostic value of troponin, D-dimer, prothrombotic, and proinflammatory markers in patients with T2DM. Methods The retrospective cohort study included 305 patients with pulmonary embolism, divided into two groups: the first group with type 2 diabetes mellitus (n=165) and the control group without type 2 diabetes mellitus (n=140). Data were collected from May 2018 to May 2023. In all patients the following parameters were analysed: anthropometric parameters, laboratory parameters (troponin, D-dimer, CRP, fibrinogen, uric acid, glucose, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides), arterial blood pressure, antiphospholipid antibodies, HOMA-IR index, CT angiography of the pulmonary artery, rate of adverse clinical events in pulmonary embolism (need for inotropic catecholamine support, fibrinolysis, cardiopulmonary resuscitation) and the rate of intrahospital mortality from pulmonary embolism. Results Patients with T2DM had elevated troponin, D-dimer, CRP, uric acid, fibrinogen, HOMA-IR and more severe clinical complications with higher mortality rates within 10 days of hospital admission. Significant predictors of PE in T2DM patients were found. Patients with pulmonary embolism in T2DM had a 4.38 times higher chance of death compared to patients with pulmonary embolism without T2DM. Conclusions Troponin, D-dimer, prothrombotic, and proinflammatory markers have good prognostic value for short-term outcomes in PE among patients with T2DM
Ray JG, Lonn E, Yi Q, Rathe A, Sheridan P, Kearon C, et al. Venous thromboembolism in association with features of the metabolic syndrome. QJM 2007;100:679–84.
2
Janisset L, Castan M, Poenou G, Lachand R, Mismetti P, Viallon A, et al. Cardiac Biomarkers in patients with acute pulmonary embolism. Medicina (Kaunas 2022;58;(541).
3
Becattini C, Agnelli G, Vedovati MC, Pruszczyk P, Casazza F, Grifoni S, et al. Multidetector computed tomography for acute pulmonary embolism: diagnosis and risk stratification in a single test. Eur Heart J 2011;32:1657–63.
4
Kahn de WKPENEJM. 2022;387:45–57.
5
Monteleone PP, Rosenfield K, Rosovsky RP. Multidisciplinary pulmonary embolism response teams and systems. Cardiovasc Diagn Ther 2016;6:662–7.
6
Yang G, Staercke C, W.C H. The effects of obesity on venous thromboembolism: a review. Open J Prev Med 2012;2:499–509.
7
Association AD. Classification and diagnosis of diabetes: medical care in diabetes. Diabetes Care 2021;44:15–33.
8
Gender-specific alterations in fibrin structure function in type 2 diabetes: associations with cardiometabolic and vascular markers. J Clin Endocrinol Metab 2012;97:2282–7.
9
Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, Del Cañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes 2014;15:444–70.
10
Schmitt VH, Hobohm L, Sivanathan V, Brochhausen C, Gori T, Münzel T, et al. Diabetes mellitus and its impact on mortality rate and outcome in pulmonary embolism. J Diabetes Investig 2022;13:725–37.
11
Fendri S, Roussel B, Lormeau B, Tribout B, Lalau JD. Insulin sensitivity, insulin action, and fibrinolysis activity in nondiabetic and diabetic obese subjects. Metabolism 1998;47:1372–5.
12
Metabolic syndrome and risk of venous thromboembolism: longitudinal investigation of thromboembolism etiology. J Thromb Haemost 2009;7:746–51.
13
Wang Y, Wang P, Li H. Correlation study of pulmonary embolism and high-density lipoprotein cholesterol. Clin Cardiol 2010;33:72–6.
14
Shifa K, J T, K WP, Liji K. A Comparative study on plasma fibrinogen and hs-crp in metabolic syndrome. Int J Clin Biochem Res 2015;2:162–5.
15
Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003;107:391–7.
16
Ozsu S, Çoşar AM, Aksoy HB, Bülbül Y, Oztuna F, Karahan SC, et al. Prognostic value of uric acid for pulmonary thromboembolism. Respir Care 2017;62:1091–6.
17
Demir OM, Ryan M, Cirillo C, Desai N, Pericao A, Sinclair H, et al. Impact and determinants of high-sensitivity cardiac troponin-T concentration in patients with COVID-19 admitted to critical care. Am J Cardiol 2021;147:129–36.
18
Kline JA, Hernandez-Nino J, Rose GA, Norton HJ, CA C. Surrogate markers for adverse outcomes in normotensive patients with pulmonary embolism. Crit Care Med 2006;34:2773–80.
19
Bulj N, Potočnjak I, Sharma M, Pintaric H, Degoricija V. Timing of troponin T measurements in triage of pulmonary embolism patients. Croat Med J 2013;54:561–8.
20
Summer R, Walsh K, Medoff BD. Obesity and pulmonary arterial hypertension: Is adiponectin the molecular link between these conditions? Pulm Circ 2011;1:440–7.
21
O’Hara A, Pozin J, Darki A, Siddiqui F, Hoppensteadt D, Walenga J, et al. Glycemic control and plasma levels of pro-inflammatory and pro-thrombotic biomarkers in diabetic patients presenting with acute pulmonary embolism. Clin Appl Thromb Hemost 2023;29;(10760296231165058).
22
Goldhaber SZ. Venous thromboembolism: epidemiology and magnitude of the problem. Best Pract Res Clin Haematol 2012;25:235–42.
23
L.M. K, E.R H. Screening and diagnosis of VTE: the more you look, the more you find? Curr Trauma Rep 2016:29–34.
24
Ageno W, Prandoni P, Romualdi E, Ghirarduzzi A, Dentali F, Pesavento R. The metabolic syndrome and the risk of venous thrombosis: a case-control study. J Thromb Haemost 2006;4:1914–8.
25
Jang MJ, Choi WI, Bang SM, Lee T, Kim YK, Ageno W, et al. Metabolic syndrome is associated with venous thromboembolism in the Korean population. Arterioscler Thromb Vasc Biol 2009;29:311–5.
26
Vayá A, Martínez-Triguero ML, España F, Todolí JA, Bonet E, Corella D. The metabolic syndrome and its individual components: its association with venous thromboembolism in a Mediterranean population. Metab Syndr Relat Disord 2011;9:197–201.
27
Borch KH, Braekkan SK, Mathiesen EB, Njølstad I, Wilsgaard T, Størmer J, et al. Abdominal obesity is essential for the risk of venous thromboembolism in the metabolic syndrome: the Tromsø study. J Thromb Haemost 2009;7:739–45.
28
Molica F, Morel S, Kwak BR, Rohner-Jeanrenaud F, Steffens S. Adipokines at the crossroad between obesity and cardiovascular disease. Thromb Haemost 2015;113:553–66.
29
Stewart LK, Kline JA. Metabolic syndrome increases risk of venous thromboembolism recurrence after acute pulmonary embolism. Ann Am Thorac Soc 2020;17:821–8.
30
MW EH, M M, S S, A IA, MM Z, OM A, et al. Adipokines: Potential therapeutic targets for vascular dysfunction in type II diabetes mellitus and obesity. J Diabetes Res 2017;2:8095–926.
31
Li X, Weber NC, Cohn DM, Hollmann MW, DeVries JH, Hermanides J, et al. Effects of Hyperglycemia and Diabetes Mellitus on Coagulation and Hemostasis. J Clin Med 2021;10;(2419).
32
Cho NH, Shaw JE, Karuranga S, Huang Y, Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 2018;138:271–81.
33
Leidi A, Bex S, Righini M, Berner A, Grosgurin O, Marti C. Risk stratification in patients with acute pulmonary embolism: current evidence and perspectives. J Clin Med 2022;30:11–2533.
34
Dhananjayan R, Koundinya KS, Malati T, Kutala VK. Endothelial dysfunction in type 2 diabetes mellitus. Indian J Clin Biochem 2016;31:372–9.
35
E DC, A C, L R, M F, TB H, O S, et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol 2019;26:25–32.
36
Sudi KM, Gallistl S, Tröbinger M, Payerl D, Weinhandl G, Muntean W, et al. The influence of weight loss on fibrinolytic and metabolic parameters in obese children and adolescents. J Pediatr Endocrinol Metab 2001;14:85–94.
37
Fujii S, Goto D, Zaman T, Ishimori N, Watano K, Kaneko T, et al. Diminished fibrinolysis and thrombosis: clinical implications for accelerated atherosclerosis. Journal of Atherosclerosis and Thrombosis 1998;5:76–81.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
